Aztreonam (Cayston) Summary of therapeutic value

For the treatment of adult patients with cystic fibrosis and a chronic P. aeruginosa infection, the inhalation of aztreonam has the same therapeutic value as the inhalation of tobramycin or colistin. The (in part) favourable effects of aztreonam, and the lack of unfavourable effects, are insufficient for an added therapeutic value, because there is only one, open, efficacy study and because experience with the product is limited. The use of aztreonam on children has been insufficiently studied.